23P CDK4/6 inhibition and endocrine therapy (ET) in the HER2-enriched subtype (HER2-E) in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (ABC): A retrospective analysis of real-world data
Titel:
23P CDK4/6 inhibition and endocrine therapy (ET) in the HER2-enriched subtype (HER2-E) in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (ABC): A retrospective analysis of real-world data
Auteur:
Martínez-Sáez, O. Tolosa, P. Sánchez De Torre, A. Pascual, T. Brasó-Maristany, F. Rodriguez Hernandez, A. Parrilla, L. Roncero, A.M. Ruano, Y. Chic, N. Schettini, F. Laguna, J.C. Sanfeliu Torres, E. Gonzalez-Farre, B. Vidal, M. Adamo, B. Guillen Sacoto, M.C. Muñoz, M. Prat, A. Ciruelos, E.M.